iMMAGINE-1
Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma
What's the purpose of the trial?
A Phase II study of CART-ddBCMA for patients with relapsed or refractory multiple myeloma. CART-ddBCMA is a BCMA-directed CAR-T cell therapy.
Accepting patients
![](https://maps.googleapis.com/maps/api/staticmap?key=AIzaSyDXH19UJTDtS-I9fdYHjFXupEiuQkBgRPk&size=520x280&scale=1&maptype=raodmap&markers=icon%3Ahttps%3A%2F%2Fassets.sparkcures.com%2Fimg%2Fmaps%2Fhospital-default.png%7C42.363201%2C-71.068802%7C43.060799%2C-88.028397%7C34.749199%2C-92.321999%7C28.0644%2C-82.421501%7C33.909199%2C-84.353996%7C41.7883%2C-87.604599%7C39.2882%2C-76.624802%7C39.295898%2C-76.5933%7C42.339699%2C-71.105003%7C42.337502%2C-71.108101%7C42.3522%2C-83.057098%7C40.8839%2C-74.055603%7C35.2062%2C-80.838203%7C45.498901%2C-122.670998%7C32.812157%2C-96.8405%7C29.707199%2C-95.396698%7C40.772598%2C-111.834%7C43.076401%2C-89.432198%7C33.581391%2C-111.883082%7C39.746535%2C-104.966175)
Participating Centers
There are 20 centers participating in this trial. Enter a location below to find the closest center.
Experimental Treatments
Learn more about the experimental treatments being evaluated in this clinical trial.
- Anitocabtagene Autoleucel is a BCMA directed CAR T cell therapy in development for multiple myeloma.
Arms / Cohorts
Explore eligibility, treatments and learn more about potential cohorts.
Accepting patients
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.